CD44表达是肝内胆管癌患者手术切除后预后的一个因素。
CD44 Expression Is a Prognostic Factor in Patients with Intrahepatic Cholangiocarcinoma After Surgical Resection.
作者信息
Morine Yuji, Imura Satoru, Ikemoto Tetsuya, Iwahashi Shuichi, Saito Y U, Shimada Mitsuo
机构信息
Department of Surgery, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan
Department of Surgery, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan.
出版信息
Anticancer Res. 2017 Oct;37(10):5701-5705. doi: 10.21873/anticanres.12007.
BACKGROUND/AIM: Cancer stem cells (CSC) plays an important role in various kinds of cancers. The aim of this study was to clarify the role of CD44 expression in intrahepatic cholangiocarcinoma (IHCC) as a marker of CSCs.
MATERIALS AND METHODS
Thirty-five patients with IHCC patients who underwent hepatectomy were evaluated. CD44 expression was determined immunohistochemically. The patients were divided into a CD44-positive group (n=22) or CD44-negative group (n=13). Clinicopathological variables including prognosis were compared between the two groups.
RESULTS
The CD44-positive group had a worse prognosis than the CD44-negative group (5-year survival: 19.3% vs. 55.5%, respectively, p=0.016), although no difference in the background variables was observed. In multivariate analysis, CD44-positivity was identified as an independent prognostic factor (hazard ratio=3.676, p=0.034).
CONCLUSION
These data suggest that CD44-positivity might be a candidate CSC marker in IHCC and a prognostic indicator.
背景/目的：癌症干细胞（CSC）在各类癌症中发挥着重要作用。本研究旨在阐明CD44表达在肝内胆管癌（IHCC）中作为癌症干细胞标志物的作用。
材料与方法
对35例行肝切除术的IHCC患者进行评估。采用免疫组织化学法测定CD44表达。将患者分为CD44阳性组（n = 22）和CD44阴性组（n = 13）。比较两组间包括预后在内的临床病理变量。
结果
CD44阳性组的预后比CD44阴性组差（5年生存率分别为19.3%和55.5%，p = 0.016），尽管在背景变量方面未观察到差异。多因素分析显示，CD44阳性被确定为独立的预后因素（风险比 = 3.676，p = 0.034）。
结论
这些数据表明，CD44阳性可能是IHCC中癌症干细胞的一个候选标志物及预后指标。
Zotero 插件